Imaging     Angiogenesis     Retinal Pigment Epithelial     Treatment    


AMD is widely accepted to be a chronic inflammatory disease that begins in Bruch’s membrane, spreads to cause dysfunction of the retinal pigment epithelium (RPE) and finally allows ingress of choroidal new vessels (CNV) with catastrophic haemorrhage into the retina. Our current treatment options target either the RPE or the CNV. For the former, we are developing a new surgical technique to replace the RPE before the overlying neurosensory retina is compromised. For CNV we are assessing inhibitors of vascular endothelial growth factors (VEGF) and other new molecular treatments in clinical trials. We are also developing RNA interference and new cutting edge biotechnology, such as non-integrating lentiviral vectors for gene delivery. We have recently completed two clinical trials to assess surgical removal of CNV and in the laboratory we have developed a new stem cell method of photoreceptor transplantation, which could potentially restore sight in end-stage cases of AMD.

IO researchers in this area:
Professor Robin Ali
Mr G William Aylward
Dr James Bainbridge
Professor Alan Bird
Professor Pete Coffey
Mr Lyndon Da Cruz
Dr Imre Lengyel
Professor Phil Luthert
Mr Robert MacLaren
Professor Steven Moss
Professor Gary Rubin
Mr Adnan Tufail
Mr Andrew Webster

You need to upgrade your Flash Player